Chapter 38
Basics of Antiplatelet and Anticoagulant Therapy for Cardiovascular Disease
Piera Capranzano,
Dominick J. Angiolillo,
Piera Capranzano
Search for more papers by this authorDominick J. Angiolillo
Search for more papers by this authorPiera Capranzano,
Dominick J. Angiolillo,
Piera Capranzano
Search for more papers by this authorDominick J. Angiolillo
Search for more papers by this authorBook Editor(s):George D. Dangas MD, MACC, MSCAI, FAHA, FESC,
Carlo Di Mario MD, PhD, FRCP, FACC, FSCAI, FESC,
Holger Thiele MD,
Peter Barlis MBBS, MPH, PHD, FACC, FESC, FRACP,
Tayo Addo MD, Bimmer Claessen MD, Christian Hengstenberg MD, Nicholas Kipshidze MD,
George D. Dangas MD, MACC, MSCAI, FAHA, FESC
Professor of Medicine (Cardiology) & Surgery (Vascular) Professor of Cardiology Adjunct Professor of Internal Medicine
Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, NY, USA
National Kapodistrian University of Athens, Greece
Medical University of Vienna, Austria
Search for more papers by this authorCarlo Di Mario MD, PhD, FRCP, FACC, FSCAI, FESC
Professor of Cardiology Director of the Structural Interventional Cardiology Division Honorary Consultant
University of Florence
University Hospital Careggi, Florence, Italy
Cardiologist Royal Brompton Hospital, London, UK
Search for more papers by this authorHolger Thiele MD
Professor of Cardiology at University of Leipzig
Heart Center Leipzig at University of Leipzig, Leipzig, Germany
Search for more papers by this authorPeter Barlis MBBS, MPH, PHD, FACC, FESC, FRACP
Professor of Cardiology Interventional Cardiologist
University of Melbourne, Melbourne, Victoria, Australia
St Vincent's & Northern Hospitals Victoria, Australia
Search for more papers by this authorFirst published: 06 May 2022
Summary
Key mechanisms underlying the clinical manifestation of atherosclerotic cardiovascular disease include the interaction of platelets and coagulation factors with vessel endothelium and other components of the arterial wall. Thus, several antiplatelet and anticoagulatnt agents have been developed to prevent vascular thrombotic complications of atherosclerotic disease involving the coronary, cerebrovascular, and peripheral arteries. This chapter reviews the pathophysiology of the arterial thrombosis cascade and provides a general overview of current and novel antiplatelet and anticoagulant agents used for secondary cardiovascular prevention.
References
- Davi G , Patrono C . Platelet activation and atherothrombosis . N Engl J Med 2007 ; 357 : 2482 – 2494 .
- Libby P , Theroux P . Pathophysiology of coronary artery disease . Circulation 2005 ; 111 : 3481 – 3488 .
- Brass LF . Thrombin and platelet activation . Chest 2003 ; 124 : 18S – 25S .
- Varga-Szabo D , Pleines I , Nieswandt B . Cell adhesion mechanisms in platelets . Arterioscler Thromb Vasc Biol 2008 ; 28 : 403 – 12 .
- Angiolillo DJ , Ueno M , Goto S . Basic principles of platelet biology and clinical implications . Circ J 2010 ; 74 : 597 – 607 .
- Brass LF . Thrombin and platelet activation . Chest 2003 ; 124 : 18S – 25S .
- Angiolillo DJ , Ferrerio JL . Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents . Am J Cardiovasc Drugs 2013 ; 13 : 233 – 250 .
- Dorsam RT , Kunapuli SP . Central role of the P2Y12 receptor in platelet activation . J Clin Invest 2004 ; 113 : 340 – 345 .
- Offermanns S. Activation of platelet function through G protein-coupled receptors . Circ Res 2006 ; 99 : 1293 – 1304 .
- Mackman N , Tilley RE , Key NS . Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis . Arterioscler Thromb Vasc Biol 2007 ; 27 : 1687 – 1693 .
- Monroe DM , Hoffman M , Roberts HF . Platelet and thrombin generation . Arterioscler Thromb Vasc Biol 2002 ; 22 : 1381 – 1389 .
- Brummel KE , Paradis SG , Butenas S , Mann KG . Thrombin functions during tissue factor-induced blood coagulation . Blood 2002 ; 100 : 148 – 152 .
- Mann KG . Thrombin formation . Chest 2003 ; 124 : 4S – 10S .
- Derian CK , Damiano BP , Addo MF , et al . Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates . J Pharmacol Exp Ther 2003 ; 304 : 855 – 861 .
- Kato Y , Kita Y , Hirasawa-Taniyama Y , et al . Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig . Eur J Pharmacol 2003 ; 473 : 163 – 169 .
- Vandendries ER , Hamilton JR , Coughlin SR , et al . Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis . Proc Natl Acad Sci U S A 2007 ; 104 : 288 – 292 .
- Coughlin SR . Protease-activated receptors in hemostasis, thrombosis and vascular biology . J Thromb Haemost 2005 ; 3 : 1800 – 1814 .
- Leger AJ , Covic L , Kuliopulos A . Protease-activated receptors in cardiovascular diseases . Circulation 2006 ; 114 : 1070 – 1077 .
- Patrono C. Aspirin as an antiplatelet drug . N Engl J Med 1994 ; 330 : 1287 – 1294 .
- Baigent C , Blackwell L , Collins R , et al . Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials . Lancet 2009 ; 373 : 1849 – 1860 .
- Neumann FJ , Sousa-Uva M , Ahlsson A , et al . 2018 ESC/EACTS Guidelines on myocardial revascularization . Eur Heart J 2019 ; 40 : 87 – 165 .
- Levine GN , Bates ER , Bittl JA , et al . 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery . Circulation 2016 ; 134 : e123 – 55 .
- Capodanno D , Mehran R , Valgimigli M , et al . Aspirin-free Strategies in Cardiovascular Disease and Cardioembolic Stroke Prevention . Nat Rev Cardiol 2018 ; 15 : 480 – 496 .
- Mason PJ , Jacobs AK , Freedman JE . Aspirin resistance and atherothrombotic disease . J Am Coll Cardiol 2005 ; 46 : 986 – 993 .
- Ferreiro JL , Angiolillo DJ . New directions in antiplatelet therapy . Circ Cardiovasc Interv 2012 ; 5 : 433 – 45 .
- Bertrand ME , Rupprecht HJ , Urban P , Gershlick AH ; CLASSICS Investigators . Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS) . Circulation 2000 ; 102 : 624 – 629 .
- Cadroy Y , Bossavy JP , Thalamas C , Sagnard L , Sakariassen K , Boneu B . Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans . Circulation 2000 ; 101 : 2823 – 2828 .
- Yusuf S , Zhao F , Mehta SR , Chrolavicius S , Tognoni G , Fox KK . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation . N Engl J Med 2001 ; 345 : 494 – 502 .
- Chen ZM , Jiang LX , Chen YP , et al . Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial . The Lancet 2005 ; 366 : 1607 – 1621 .
- Sabatine MS , Cannon CP , Gibson CM , et al . Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation . N Engl J Med 2005 ; 352 : 1179 – 1189 .
- Mehta SR , Yusuf S , Peters RJ , et al . Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study . The Lancet 2001 ; 358 : 527 – 533 .
- Steinhubl SR , Berger PB , Mann JT 3rd , et al . Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial . JAMA 2002 ; 288 : 2411 – 2420 .
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee . The Lancet 1996 ; 348 : 1329 – 1339 .
- Bhatt DL , Fox KA , Hacke W , et al . Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events . N Engl J Med 2006 ; 354 : 1706 – 1717 .
- Bhatt DL , Flather MD , Hacke W , et al . Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial . J Am Coll Cardiol 2007 ; 49 : 1982 – 1988 .
- Watanabe H , Domei T , Morimoto T , et al . Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial JAMA 2019 ; 321 : 2414 – 2427 .
- Hahn JY , Song YB , Oh JH , et al . Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial . JAMA 2019 ; 321 : 2428 – 2437 .
- Ferreiro JL , Angiolillo DJ . Clopidogrel response variability: current status and future directions . Thromb Haemost 2009 ; 102 : 7 – 14 .
- Capranzano P , Ferreiro JL , Angiolillo DJ . Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention . Expert Rev Cardiovasc Ther 2009 ; 7 : 361 – 369 .
- Brandt JT , Payne CD , Wiviott SD , et al . A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation . Am Heart J 2007 ; 153 : 66.e9 – 16 .
- Wiviott SD , Trenk D , Frelinger AL , et al . Prasugrel compared with high loadingand maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial . Circulation 2007 ; 116 : 2923 – 2932 .
- Wiviott SD , Braunwald E , McCabe CH , et al . Prasugrel versus clopidogrel in patients with acute coronary syndromes . N Engl J Med 2007 ; 357 : 2001 – 2015 .
- Roe MT , Armstrong PW , Fox KA , et al ; TRILOGY ACS Investigators . Prasugrel versus clopidogrel for acute coronary syndromes without revascularization . N Engl J Med 2012 ; 367 : 1297 – 1309 .
- Montalescot G , Bolognese L , Dudek D , et al . Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes . N Engl J Med 2013 ; 369 : 999 – 1010 .
- Capodanno D , Dharmashankar K , Angiolillo DJ . Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist . Expert Rev Cardiovasc Ther 2010 ; 8 : 151 – 158 .
- Cattaneo M , Schulz R , Nylander S . Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance . J Am Coll Cardiol 2014 ; 63 : 2503 – 2509 .
- Wallentin L , Becker RC , Budaj A , et al . Ticagrelor versus clopidogrel in patients with acute coronary syndromes . N Engl J Med 2009 ; 361 : 1045 – 1057 .
- Bonaca MP , Bhatt DL , Cohen M , et al . PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction . N Engl J Med 2015 ; 372 : 1791 – 1800 .
- Steg PG , Bhatt DL , Simon T , et al . THEMIS Steering Committee and Investigators. Ticagrelor in Patients with Stable Coronary Disease and Diabetes . N Engl J Med 2019 ; 381 : 1309 – 1320 .
- Hiatt WR , Fowkes FG , Heizer G , et al . EUCLID Trial Steering Committee and Investigators. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease . N Engl J Med 2017 ; 376 : 32 – 40 .
- Johnston SC , Amarenco P , Albers GW , et al . SOCRATES Steering Committee and Investigators. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack . N Engl J Med 2016 ; 375 : 35 – 43 .
- Mehran R , Baber U , Sharma SK , et al . Ticagrelor with or without Aspirin in High-Risk Patients after PCI . N Engl J Med 2019 ; 381 : 2032 – 2042 .
- Presented by Dr. Byeong-Keuk Kim at the American College of Cardiology Virtual Annual Scientific Session Together With World Congress of Cardiology (ACC 2020/WCC) , March 30, 2020 .
- Ferreiro JL , Ueno M , Angiolillo DJ . Cangrelor: a review on its mechanism of action and clinical development . Expert Rev Cardiovasc Ther 2009 ; 7 : 1195 – 1201 .
- Harrington RA , Stone GW , McNulty S , et al . Platelet inhibition with cangrelor in patients undergoing PCI . N Engl J Med 2009 ; 361 : 2318 – 2329 .
- Bhatt DL , Lincoff AM , Gibson CM , et al ; CHAMPION PLATFORM Investigators . Intravenous platelet blockade with cangrelor during PCI . N Engl J Med 2009 ; 361 : 2330 – 2341 .
- Bhatt DL , Stone GW , Mahaffey KW , et al ; the CHAMPION PHOENIX Investigators . Effect of platelet inhibition with cangrelor during PCI on ischemic events . N Engl J Med 2013 368 : 1303 – 1313 .
- Steg PG , Bhatt DL , Hamm CW , et al . Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data . The Lancet 2013 ; 382 : 1981 – 1992 .
- Franchi F , Rollini F , Rivas A , et al . Platelet Inhibition with Cangrelor and Crushed Ticagrelor in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of the CANTIC Study . Circulation 2019 ; 139 : 1661 – 70 .
- Capranzano P , Francaviglia B , Angiolillo DJ . Pharmacodynamics During Transition Between Platelet P2Y12 Inhibiting Therapies . Interv Cardiol Clin 2019 ; 8 : 321 – 340 .
- Angiolillo DJ , Firstenberg MS , Price MJ , et al . Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial . JAMA 2012 ; 307 : 265 – 274 .
- Kleiman NS . Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors . Am Heart J 1999 ; 138 : 263 – 275 .
- Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators . The Lancet 1998 ; 352 : 87 – 92 .
- Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation . N Engl J Med 1994 ; 330 : 956 – 961 .
- Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators . N Engl J Med 1997 ; 336 : 1689 – 1696 .
- Stone GW , Grines CL , Cox DA , et al . Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction . N Engl J Med 2002 ; 346 : 957 – 966 .
- Kastrati A , Mehilli J , Schuhlen H , et al . A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel . N Engl J Med 2004 ; 350 : 232 – 238 .
- Kastrati A , Mehilli J , Neumann FJ , et al . Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial . JAMA 2006 ; 295 : 1531 – 1538 .
- Mehilli J , Kastrati A , Schulz S , et al . Bavarian Reperfusion Alternatives Evaluation-3 (BRAVE-3) Study Investigators. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial . Circulation 2009 ; 119 : 1933 – 1940 .
- Stone GW , Maehara A , Witzenbichler B , et al .; INFUSE-AMI Investigators . Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial . JAMA 2012 ; 307 : 1817 – 1826 .
- Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II . The Lancet 1997 ; 349 : 1422 – 1428 .
- PURSUIT Trial Investigators . Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes: Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy . N Engl J Med 1998 ; 339 : 436 – 443 .
- ESPRIT Investigators . Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial . The Lancet 2000 ; 356 : 2037 – 2044 .
- Giugliano RP , White JA , Bode C , et al . Early versus delayed, provisional eptifibatide in acute coronary syndromes . N Engl J Med 2009 ; 360 : 2176 – 2190 .
- Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction . N Engl J Med 1998 ; 338 : 1488 – 1497 .
- Topol EJ , Moliterno DJ , Herrmann HC , et al . Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization . N Engl J Med 2001 ; 344 : 1888 – 1894 .
- Meadows TA , Bhatt DL . Clinical aspects of platelet inhibitors and thrombus formation . Circ Res 2007 ; 100 : 1261 – 1275 .
- Angiolillo DJ , Capranzano P , Goto S , et al . A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study . Eur Heart J 2008 ; 29 : 2202 – 2211 .
- Lee S , Park S , Kim Y , et al . Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients) . J Am Coll Cardiol 2008 ; 51 : 1181 – 1187 .
- Aktas B , Utz A , Hoenig-Liedl P , Walter U , Geiger J . Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies . Stroke 2003 ; 34 : 764 – 769 .
- Diener HC , Cunha L , Forbes C , Sivenius J , Smets P , Lowenthal A . European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke . J Neurol Sci 1996 ; 143 : 1 – 13 .
- Halkes PH , van Gijn J , Kappelle LJ , Koudstaal PJ , Algra A . Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial . The Lancet 2006 ; 367 : 1665 – 1673 .
- Sacco RL , Diener HC , Yusuf S , et al . Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke . N Engl J Med 2008 ; 359 : 1238 – 1251 .
- Angiolillo DJ , Capodanno D , Goto S . Platelet thrombin receptor antagonism and atherothrombosis . Eur Heart J 2010 ; 31 : 17 – 28 .
- Tricoci P , Huang Z , Held C , et al . the TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes . N Engl J Med 2012 ; 366 : 20 – 33 .
- Morrow DA , Braunwald E , Bonaca MP , et al ; TRA 2P–TIMI 50 Steering Committee and Investigators . Vorapaxar in the secondary prevention of atherothrombotic events . N Engl J Med 2012 ; 366 : 1404 – 1413 .
- Morrow DA , Alberts MJ , Mohr JP , et al ; for the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–TIMI 50 Steering Committee and Investigators . Efficacy and safety of vorapaxar in patients with prior ischemic stroke . Stroke 2013 ; 44 ( 3 ): 691 – 698 .
- Scirica BM , Bonaca MP , Braunwald E , et al ; TRA 2°P-TIMI 50 Steering Committee Investigators . Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial . The Lancet 2012 ; 380 : 1317 – 1324 .
- Bonaca MP , Morrow DA , Braunwald E . Vorapaxar for secondary prevention in patients with peripheral artery disease: results from the peripheral artery disease cohort of the TRA 2°P-TIMI 50 trial . American Heart Association Emerging Science Series Report . Available at http://my.americanheart.org/professional/Sessions/AdditionalMeetings/EmergingScienceSeries/2012-Emerging-Science-Series%C2%97-June-20-2012_UCM_441183_Article.jsp
- O'Donoghue ML , Bhatt DL , Wiviott SD , et al; LANCELOT-ACS Investigators . Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial . Circulation 2011 ; 123 : 1843 – 1853 .
- Wiviott SD , Flather MD , O'Donoghue ML , et al ; LANCELOT-CAD Investigators . Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial . Circulation 2011 ; 123 : 1854 – 1863 .
- Capodanno D , Bhatt DL , Goto S , et al . Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials . J Thromb Haemost 2012 ; 10 : 2006 – 2015 .
- Chamorro A. TP receptor antagonism: a new concept in atherothrombosis and stroke prevention . Cerebrovasc Dis 2009 ; 27 ( Suppl 3 ): 20 – 27 .
- Eikelboom JW , Weitz JI . New anticoagulants . Circulation 2010 ; 121 : 1523 – 1532 .
- Bjork I , Lindahl U . Mechanism of the anticoagulant action of heparin . Mol Cell Biochem 1982 ; 48 : 161 – 182 .
- Choay J , Petitou M , Lormeau JC , Sinay P , Casu B , Gatti G . Structure–activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity . Biochem Biophys Res Commun 1983 ; 116 : 492 – 499 .
- Di Nisio M , Middeldorp S , Buller HR . Direct thrombin inhibitors . N Engl J Med 2005 ; 353 : 1028 – 1040 .
- Oldgren J , Budaj A , Granger CB , et al ; RE-DEEM Investigators . Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial . Eur Heart J 2011 ; 32 : 2781 – 2789 .
- Witting JI , Bourdon P , Brezniak DV , Maraganore JM , Fenton JW 2nd. Thrombinspecific inhibition by and slow cleavage of hirulog-1 . Biochem J 1992 ; 283 : 737 – 743 .
- Nuhrenberg TG , Hochholzer W , Mashayekhi K , Ferenc M , Neumann FJ . Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes: A meta-analysis of randomized-controlled trials . Clin Res Cardiol 2018 ; 107 : 807 – 815 .
- Yusuf S , Mehta SR , Chrolavicius S , et al . Comparison of fondaparinux and enoxaparin in acute coronary syndromes . N Engl J Med 2006 ; 354 : 1464 – 1476 .
- Steg PG , Jolly SS , Mehta SR , et al . Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial . JAMA 2010 ; 304 : 1339 – 1349 .
- Yusuf S , Mehta SR , Chrolavicius S , et al . Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial . JAMA 2006 ; 295 : 1519 – 1530 .
- Sabatine MS , Antman EM , Widimsky P , et al . Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial . The Lancet 2009 ; 374 : 787 – 795 .
- Steg PG 1, Mehta SR , Pollack CV Jr, et al . Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial . JAMA 2013 ; 310 : 1145 – 1155 .
- Mega JL , Braunwald E , Wiviott SD , et al .; ATLAS ACS 2–TIMI 51 Investigators . Rivaroxaban in patients with a recent acute coronary syndrome . N Engl J Med 2012 ; 366 : 9 – 19 .
- Eikelboom JW , Connolly SJ , Bosch J , et al.; COMPASS Investigators . Rivaroxaban with or without aspirin in stable cardiovascular disease . N Engl J Med 2017 ; 377 : 1319 – 1330 .
- Bonaca MP , Bauersachs RM , Anand SS , et al. Rivaroxaban in Peripheral Artery Disease after Revascularization . N Engl J Med 2020 ; 382 : 1994 – 2004 .
- Alexander JH , Lopes RD , James S , et al .; APPRAISE-2 Investigators . Apixaban with antiplatelet therapy after acute coronary syndrome . N Engl J Med 2011 ; 365 : 699 – 708 .
- Povsic TJ , Vavalle JP , Aberle LH , et al.; on behalf of the RADAR Investigators . A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial . Eur Heart J 2013 ; 34 : 2481 – 2489 .
